HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval ASCO 2023 - 3 days (New C3) trastuzumab + pertuzumab Sensitive : A1 ASCO 2023 - 3d	trastuzumab + pertuzumab Sensitive: A1 - Approval ASCO 2023 - 3 days trastuzumab + pertuzumab Sensitive : A1 ASCO 2023 - 3 days - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) sacituzumab govitecan-hziy Sensitive : A1 ASCO 2023 - 3d	sacituzumab govitecan-hziy Sensitive: A1 - Approval ASCO 2023 - 3 days sacituzumab govitecan-hziy Sensitive : A1 ASCO 2023 - 3 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) abemaciclib Sensitive : A1 ASCO 2023 - 3d	abemaciclib Sensitive: A1 - Approval ASCO 2023 - 3 days abemaciclib Sensitive : A1 ASCO 2023 - 3 days - (New B)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials ASCO 2023 - 3 days (New B) palbociclib Sensitive : B ASCO 2023 - 3d	palbociclib Sensitive: B - Late Trials ASCO 2023 - 3 days palbociclib Sensitive : B ASCO 2023 - 3 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	G1T38 Sensitive: B - Late Trials ASCO 2023 - 3 days (New B) G1T38 Sensitive : B ASCO 2023 - 3d	G1T38 Sensitive: B - Late Trials ASCO 2023 - 3 days G1T38 Sensitive : B ASCO 2023 - 3 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib Sensitive: B - Late Trials ASCO 2023 - 3 days (New C3) dalpiciclib Sensitive : B ASCO 2023 - 3d	dalpiciclib Sensitive: B - Late Trials ASCO 2023 - 3 days dalpiciclib Sensitive : B ASCO 2023 - 3 days - (New C3)
ERBB3 expression	Breast Cancer	ERBB3 expression	Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 3 days (New C3) U3-1402 Sensitive : C2 ASCO 2023 - 3d	U3-1402 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 3 days U3-1402 Sensitive : C2 ASCO 2023 - 3 days - (New C3)
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) DF1001 Sensitive : C3 ASCO 2023 - 3d	DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days DF1001 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Resistant: A2 - Guideline ASCO.org - 1 week (New A2) alpelisib Resistant : A2 ASCO.org - 1wk	alpelisib Resistant: A2 - Guideline ASCO.org - 1 week alpelisib Resistant : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	elacestrant Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) elacestrant Sensitive : A2 ASCO.org - 1wk	elacestrant Sensitive: A2 - Guideline ASCO.org - 1 week elacestrant Sensitive : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) everolimus Sensitive : A2 ASCO.org - 1wk	everolimus Sensitive: A2 - Guideline ASCO.org - 1 week everolimus Sensitive : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) tamoxifen Sensitive : A2 ASCO.org - 1wk	tamoxifen Sensitive: A2 - Guideline ASCO.org - 1 week tamoxifen Sensitive : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) Aromatase inhibitor Sensitive : A2 ASCO.org - 1wk	Aromatase inhibitor Sensitive: A2 - Guideline ASCO.org - 1 week Aromatase inhibitor Sensitive : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) fulvestrant Sensitive : A2 ASCO.org - 1wk	fulvestrant Sensitive: A2 - Guideline ASCO.org - 1 week fulvestrant Sensitive : A2 ASCO.org - 1 week - (New A2)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval J Clin Oncol - 1 week (New C3) ribociclib Sensitive : A1 J Clin Oncol - 1wk	ribociclib Sensitive: A1 - Approval J Clin Oncol - 1 week ribociclib Sensitive : A1 J Clin Oncol - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria Ann Oncol - 1 week (New C3) U3-1402 Sensitive : C2 Ann Oncol - 1wk	U3-1402 Sensitive: C2 – Inclusion Criteria Ann Oncol - 1 week U3-1402 Sensitive : C2 Ann Oncol - 1 week - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	enzalutamide capsule + fulvestrant Sensitive: C3 – Early Trials NPJ Breast Cancer - 1 week (New C3) enzalutamide capsule + fulvestrant Sensitive : C3 NPJ Breast Cancer - 1wk	enzalutamide capsule + fulvestrant Sensitive: C3 – Early Trials NPJ Breast Cancer - 1 week enzalutamide capsule + fulvestrant Sensitive : C3 NPJ Breast Cancer - 1 week - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	tucatinib Sensitive: B - Late Trials J Natl Cancer Inst - 2 weeks (New D) tucatinib Sensitive : B J Natl Cancer Inst - 2wk	tucatinib Sensitive: B - Late Trials J Natl Cancer Inst - 2 weeks tucatinib Sensitive : B J Natl Cancer Inst - 2 weeks - (New D)
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval NICE - 2 weeks (New A2) olaparib Sensitive : A1 NICE - 2wk	olaparib Sensitive: A1 - Approval NICE - 2 weeks olaparib Sensitive : A1 NICE - 2 weeks - (New A2)
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval NICE - 2 weeks (New A2) olaparib Sensitive : A1 NICE - 2wk	olaparib Sensitive: A1 - Approval NICE - 2 weeks olaparib Sensitive : A1 NICE - 2 weeks - (New A2)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline JAMA Oncol - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : A2 JAMA Oncol - 2wk	trastuzumab + pertuzumab Sensitive: A2 - Guideline JAMA Oncol - 2 weeks trastuzumab + pertuzumab Sensitive : A2 JAMA Oncol - 2 weeks - (New C3)
TSC2 C1450G	HER2 Positive Breast Cancer	TSC2 C1450G	HER2 Positive Breast Cancer	palbociclib + lapatinib Sensitive: D – Preclinical NPJ Breast Cancer - 2 weeks (New D) palbociclib + lapatinib Sensitive : D NPJ Breast Cancer - 2wk	palbociclib + lapatinib Sensitive: D – Preclinical NPJ Breast Cancer - 2 weeks palbociclib + lapatinib Sensitive : D NPJ Breast Cancer - 2 weeks - (New D)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TCHP Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) TCHP Sensitive : A2 ESMO-BC 2023 - 3wk	TCHP Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks TCHP Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) trastuzumab + lapatinib Sensitive : A2 ESMO-BC 2023 - 3wk	trastuzumab + lapatinib Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks trastuzumab + lapatinib Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) Aromatase inhibitor Sensitive : A2 ESMO-BC 2023 - 3wk	Aromatase inhibitor Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks Aromatase inhibitor Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
PD-L1 overexpression	Triple Negative Breast Cancer	PD-L1 overexpression	Triple Negative Breast Cancer	pembrolizumab Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New B) pembrolizumab Sensitive : B ESMO-BC 2023 - 3wk	pembrolizumab Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks pembrolizumab Sensitive : B ESMO-BC 2023 - 3 weeks - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	AZD5363 Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New B) AZD5363 Sensitive : B ESMO-BC 2023 - 3wk	AZD5363 Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks AZD5363 Sensitive : B ESMO-BC 2023 - 3 weeks - (New B)
HER-2 underexpression + ER underexpression	Breast Cancer	HER-2 underexpression + ER underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New B) fam-trastuzumab deruxtecan-nxki Sensitive : B ESMO-BC 2023 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : B ESMO-BC 2023 - 3 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO-BC 2023 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) trastuzumab Sensitive : A1 ESMO-BC 2023 - 3wk	trastuzumab Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks trastuzumab Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) neratinib Sensitive : A1 ESMO-BC 2023 - 3wk	neratinib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks neratinib Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) palbociclib Sensitive : A1 ESMO-BC 2023 - 3wk	palbociclib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks palbociclib Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 ESMO-BC 2023 - 3wk	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) capecitabine Sensitive : A2 ESMO-BC 2023 - 3wk	capecitabine Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks capecitabine Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New C3) pertuzumab + ado-trastuzumab emtansine Sensitive : B ESMO-BC 2023 - 3wk	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks pertuzumab + ado-trastuzumab emtansine Sensitive : B ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New C3) trastuzumab-dkst Sensitive : B ESMO-BC 2023 - 3wk	trastuzumab-dkst Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks trastuzumab-dkst Sensitive : B ESMO-BC 2023 - 3 weeks - (New C3)
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	olaparib Sensitive: C1 - Off-label ESMO-BC 2023 - 3 weeks (New C3) olaparib Sensitive : C1 ESMO-BC 2023 - 3wk	olaparib Sensitive: C1 - Off-label ESMO-BC 2023 - 3 weeks olaparib Sensitive : C1 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine + vinorelbine tartrate Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) capecitabine + vinorelbine tartrate Sensitive : C2 ESMO-BC 2023 - 3wk	capecitabine + vinorelbine tartrate Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks capecitabine + vinorelbine tartrate Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ZW25 Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) ZW25 Sensitive : C2 ESMO-BC 2023 - 3wk	ZW25 Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks ZW25 Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + atezolizumab + pertuzumab Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) trastuzumab + atezolizumab + pertuzumab Sensitive : C2 ESMO-BC 2023 - 3wk	trastuzumab + atezolizumab + pertuzumab Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks trastuzumab + atezolizumab + pertuzumab Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 negative	Triple Negative Breast Cancer	HER-2 negative	Triple Negative Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) U3-1402 Sensitive : C2 ESMO-BC 2023 - 3wk	U3-1402 Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks U3-1402 Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) olaparib + durvalumab Sensitive : C2 ESMO-BC 2023 - 3wk	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks olaparib + durvalumab Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ARV-471 Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) ARV-471 Sensitive : C3 ESMO-BC 2023 - 3wk	ARV-471 Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks ARV-471 Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO-BC 2023 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO-BC 2023 - 3 weeks Immunotherapy Resistant : C3 ESMO-BC 2023 - 3 weeks - (New C3)
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO-BC 2023 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO-BC 2023 - 3 weeks Immunotherapy Resistant : C3 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESMO-BC 2023 - 3wk	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + HER-2 underexpression	Breast Cancer	HR positive + HER-2 underexpression	Breast Cancer	U3-1402 Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) U3-1402 Sensitive : C3 ESMO-BC 2023 - 3wk	U3-1402 Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks U3-1402 Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	abemaciclib Sensitive: C3 – Early Trials JCO Precis Oncol - 3 weeks (New C3) abemaciclib Sensitive : C3 JCO Precis Oncol - 3wk	abemaciclib Sensitive: C3 – Early Trials JCO Precis Oncol - 3 weeks abemaciclib Sensitive : C3 JCO Precis Oncol - 3 weeks - (New C3)
HR positive + ER overexpression	HER2 Negative Breast Cancer	HR positive + ER overexpression	HER2 Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) palbociclib Sensitive : C3 ESMO-BC 2023 - 3wk	palbociclib Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks palbociclib Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + ER overexpression	HER2 Negative Breast Cancer	HR positive + ER overexpression	HER2 Negative Breast Cancer	ribociclib Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) ribociclib Sensitive : C3 ESMO-BC 2023 - 3wk	ribociclib Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks ribociclib Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
CCDC6-RET fusion	Triple Negative Breast Cancer	CCDC6-RET fusion	Triple Negative Breast Cancer	pralsetinib Sensitive: C4 – Case Studies Oncologist - 3 weeks (New C4) pralsetinib Sensitive : C4 Oncologist - 3wk	pralsetinib Sensitive: C4 – Case Studies Oncologist - 3 weeks pralsetinib Sensitive : C4 Oncologist - 3 weeks - (New C4)
TROP2 overexpression	Breast Cancer	TROP2 overexpression	Breast Cancer	DS-1062a Sensitive: D – Preclinical ESMO-BC 2023 - 3 weeks (New D) DS-1062a Sensitive : D ESMO-BC 2023 - 3wk	DS-1062a Sensitive: D – Preclinical ESMO-BC 2023 - 3 weeks DS-1062a Sensitive : D ESMO-BC 2023 - 3 weeks - (New D)
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	TAC Sensitive: A1 - Approval TAC Sensitive : A1	TAC Sensitive: A1 - Approval TAC Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1

Breast Cancer

Associations(2094)

Associations
(2094)